Seattle Genetics was founded in 1998 by Clay Siegall. He is the CEO of the company. Siegall’s training has been in the scientific field with therapies for cancer as his base. He is known for his outstanding research, his practices regarding the development of different drugs, and the help he offers to patients.

Siegall’s development of conjugates for drugs combined with his leadership abilities are what secured FDA approval for him in 2011. He collaborated with a company called Takeda Pharmaceutical in securing this approval for brentuximab vedotin. This drug now has approval in over sixty different countries and has been classified as a global brand. There is also a pipeline designed for the ADC’s needed for treating cancer because of Seattle Genetics.

With Siegall in control, several license for ADC technology have been secured. Included in this are several companies who have brought in over $325 million dollars. Over twenty ADC’s of a clinical nature are being developed because of the technology of Seattle Genetics. Siegall is also at the head of raising money and has secured well over $1.2 billion dollars. This was done through both public and private finances.

Before he was one of two co-founders for Seattle Genetics, Siegall worked with Bristol-Myers Squibb Pharmaceutical. He was a member of this company from 1991 until 1997. The National Cancer Institute saw his leadership during the years of 1988 until 1991. Currently, he sits on the board of several prestigious companies.

Siegall has received several prominent awards honoring his work in the fields of science, math and computers. He was also voted as the Entrepreneur of the Year in 2012.He has written over seventy publications and is in possession of fifteen patents. His Ph.D. is in Genetics and was obtained from George Washington University. Siegall also holds a Bachelors in Science in Zoology from when he attended the University of Maryland.

Categories: Cancer Research

Comments are Closed on this Post